Focus on P2X7R in microglia: its mechanism of action and therapeutic prospects in various neuropathic pain models.

IF 4.8 2区 医学 Q1 PHARMACOLOGY & PHARMACY Frontiers in Pharmacology Pub Date : 2025-03-25 eCollection Date: 2025-01-01 DOI:10.3389/fphar.2025.1555732
Kai Zhang, Rui Ran, Cheng-Jun Zhang, Linna Wang, Hai-Hong Zhang
{"title":"Focus on P2X7R in microglia: its mechanism of action and therapeutic prospects in various neuropathic pain models.","authors":"Kai Zhang, Rui Ran, Cheng-Jun Zhang, Linna Wang, Hai-Hong Zhang","doi":"10.3389/fphar.2025.1555732","DOIUrl":null,"url":null,"abstract":"<p><p>Neuropathic pain (NP) is a common symptom of many diseases and is caused by direct or indirect damage to the nervous system. Tricyclic antidepressants and serotonin-norepinephrine reuptake inhibitors are typical drugs used in clinical practice to suppress pain. However, these drugs have drawbacks, including a short duration of action, a limited analgesic effect, and possible dependence and side effects. Therefore, developing more effective NP treatment strategies has become a priority in medical research and has attracted much research attention. P2X7 receptor (P2X7R) is a non-selective cation channel activated by adenosine triphosphate and is mainly expressed in microglia in the central nervous system. Microglial P2X7R plays an important role in pain regulation, suggesting that it could be a potential target for drug development. This review comprehensively and objectively discussed the latest research progress of P2X7R, including its structural characteristics, functional properties, relationship with microglial activation and polarization, mechanism of action, and potential therapeutic strategies in multiple NP models. This study aimed to provide in-depth insights into the association between P2X7R and NP and explore the mechanism of action of P2X7R in the pathological process of NP and the translational potential and clinical application prospects of P2X7R antagonists in pain treatment, providing a scientific basis for the precise treatment of NP.</p>","PeriodicalId":12491,"journal":{"name":"Frontiers in Pharmacology","volume":"16 ","pages":"1555732"},"PeriodicalIF":4.8000,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11975881/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Pharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fphar.2025.1555732","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Neuropathic pain (NP) is a common symptom of many diseases and is caused by direct or indirect damage to the nervous system. Tricyclic antidepressants and serotonin-norepinephrine reuptake inhibitors are typical drugs used in clinical practice to suppress pain. However, these drugs have drawbacks, including a short duration of action, a limited analgesic effect, and possible dependence and side effects. Therefore, developing more effective NP treatment strategies has become a priority in medical research and has attracted much research attention. P2X7 receptor (P2X7R) is a non-selective cation channel activated by adenosine triphosphate and is mainly expressed in microglia in the central nervous system. Microglial P2X7R plays an important role in pain regulation, suggesting that it could be a potential target for drug development. This review comprehensively and objectively discussed the latest research progress of P2X7R, including its structural characteristics, functional properties, relationship with microglial activation and polarization, mechanism of action, and potential therapeutic strategies in multiple NP models. This study aimed to provide in-depth insights into the association between P2X7R and NP and explore the mechanism of action of P2X7R in the pathological process of NP and the translational potential and clinical application prospects of P2X7R antagonists in pain treatment, providing a scientific basis for the precise treatment of NP.

Abstract Image

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
P2X7R在小胶质细胞中的作用机制及其在各种神经性疼痛模型中的治疗前景
神经性疼痛是许多疾病的常见症状,是由神经系统的直接或间接损伤引起的。三环抗抑郁药和5 -羟色胺-去甲肾上腺素再摄取抑制剂是临床常用的镇痛药物。然而,这些药物有缺点,包括作用时间短,镇痛效果有限,可能存在依赖性和副作用。因此,开发更有效的NP治疗策略已成为医学研究的重点,备受关注。P2X7受体(P2X7R)是一种由三磷酸腺苷激活的非选择性阳离子通道,主要表达于中枢神经系统的小胶质细胞。小胶质细胞P2X7R在疼痛调节中起着重要作用,这表明它可能是药物开发的潜在靶点。本文就P2X7R的结构特征、功能特性、与小胶质细胞激活和极化的关系、作用机制以及在多种NP模型中的潜在治疗策略等方面的最新研究进展进行了全面、客观的综述。本研究旨在深入了解P2X7R与NP的关系,探讨P2X7R在NP病理过程中的作用机制,以及P2X7R拮抗剂在疼痛治疗中的转化潜力和临床应用前景,为精准治疗NP提供科学依据。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Frontiers in Pharmacology
Frontiers in Pharmacology PHARMACOLOGY & PHARMACY-
CiteScore
7.80
自引率
8.90%
发文量
5163
审稿时长
14 weeks
期刊介绍: Frontiers in Pharmacology is a leading journal in its field, publishing rigorously peer-reviewed research across disciplines, including basic and clinical pharmacology, medicinal chemistry, pharmacy and toxicology. Field Chief Editor Heike Wulff at UC Davis is supported by an outstanding Editorial Board of international researchers. This multidisciplinary open-access journal is at the forefront of disseminating and communicating scientific knowledge and impactful discoveries to researchers, academics, clinicians and the public worldwide.
期刊最新文献
Cyclovirobuxine D suppresses cancer stemness in osteosarcoma with implication of the noncanonical NF-kappaB pathway. Effectiveness and safety of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma. Analysis of the clinical characteristics of direct oral anticoagulants-associated atraumatic splenic rupture. A network pharmacology-guided multi-omics and spatial single-cell framework nominates WT1 as a spironolactone-linked immune biomarker in prostate cancer. Predictive value of ALBI score and age for developing resistance to trastuzumab in HER-2-positive breast cancer patients: prediction based on a real-world case series from a single center in China.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1